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LINICAL INVESTIGATION Breast
ADJUVANT STEREOTACTIC PERMANENT SEED BREAST IMPLANT:
A BOOST SERIES IN VIEW OF PARTIAL BREAST IRRADIATION
NICOLAS JANSEN, M.D., JEAN-MARIE DENEUFBOURG, M.D., AND PHILIPPE NICKERS, PH.D.
Department of Radiation Oncology, Liege University Hospital, Liege, Belgium
Purpose: The aim of this study was to use permanent seed implants in the breast and describe our experience with
15 cases, using iodine seed implants as a tumor bed boost.
Methods and Materials: Breasts were fixed with a thermoplastic sheet, a template bridge applied, the thorax
scanned and the images rotated to be perpendicular to the implant axis. Skin, heart, and lung were delineated.
A preplan was made, prescribing 50 Gy to the clinical target volume (CTV), consisting in this boost series of
nearly a quadrant. Iodine (125) seeds were stereotactically implanted through the template, and results were
checked with a postplan computed tomographic (CT) scan.
Results: The breast was immobilized reproducibly. Simulation, scanning, and implant were performed without
difficulties. Preplan CTV D90% (the dose delivered to 90% of the CTV) was 66 Gy, and postoperative
fluoroscopic or CT scan checks were satisfactory. Pre- and postplan dose–volume histogram showed good organ
sparing: mean postplan skin, heart, and lung V30 Gy (the organ volume receiving a dose of 30 Gy) of 2  2.2
mL, 0.24  0.34 mL, and 3.5  5 mL, respectively. No short-term toxicity above Grade 1 was noted, except for
transient Grade 3 neuropathy in 1 patient.
Conclusions: Seeds remained in the right place, as assessed by fluoroscopy, absence of significant pre- to postplan
dose–volume histogram change for critical organs, and total irradiated breast volume. The method could be
proposed as a boost when high dosimetric selectivity is required (young patients after cardiotoxic chemotherapy
for left-sided cancer). This boost series was a preliminary step before testing partial breast irradiation by





















reast-conserving treatment for early breast cancer involves
urgery and adjuvant radiotherapy of the whole breast and
ften a boost to the tumor bed. The results of this classical
reatment are good, with local control rates of more than
5% at 5 years and good cosmesis (1, 2). As early breast
ancer treated by adequate surgery has few local recur-
ences outside the quadrant of the initial tumor (3), a partial
reast irradiation of the area of the initial location with a
argin can be applied. For selected low-risk patients, this
pproach has been proposed using interstitial brachyther-
py, external beam irradiation, or intraoperative irradiation
ith a mobile linear accelerator (4, 5). The suggested ad-
antages of these approaches include the precise treatment
f the target volume, the avoidance of a 5–6-week treatment
eries, less skin toxicity, and lower cardiac as well as
ulmonary doses. If patients are carefully selected and rig-
rous quality control measures are applied, the 7-year local
ontrol rates and cosmetic outcome data obtained seem to
Reprint requests to: Nicolas Jansen, M.D., Liege University
ospital, Domaine Universitaire Sart Tilman B35, B-4000 Liege,
elgium. Tel: (32) 43667462; Fax: (32) 43667952; E-mail:
icolas.jansen@chu.ulg.ac.be A
1052e at least as good as those obtained after the classic
reatments (4, 5). Randomized comparisons between the
hole breast and the partial breast irradiation approach are,
owever, still ongoing (Communicated during The GEC-
STRO [Groupe Européen de Curie Therapie-European
ociety for Therapeutic Radiology and Oncology] Pre-
eeting workshop on brachytherapy for breast cancer, May
, 2005, Budapest, Hungary, afternoon session on acceler-
ted partial breast irradiation-future directions.)
Arguments against partial breast irradiation include the
resent difficulty in accurately defining the clinical target
olume (CTV) and the possible migration of markers or of
ny other material that is placed in the tumor bed, such as
eeds (6). Using experience gained from prostate implants,
e developed a permanent seed implantation technique for
he breast based on a stereotactic approach—“stereotactic”
eing defined as “a technique for surgical treatment or
cientific investigation that permits the accurate positioning
f probes inside . . . the body, based on three-dimensional
iagrams” (7). Although the value of this implant for partial
Conflict of interest: A grant was received from IBt, which also
rovided the implanted seeds.









































































1053Breast adjuvant permanent seed implant ● N. JANSEN et al.reast irradiation will be tested in a future phase II study, we
roposed this particularly selective brachytherapy technique
which is currently used in prostate cancer) to patients as an




After external beam adjuvant whole-breast radiotherapy, a boost
as proposed owing to the presence of one or more risk factors
hat are possibly associated with local relapse. These factors in-
luded the patient being less than 50 years of age, resection
argins that were considered to be insufficient (unknown or pos-
tive margins or margins of less than 2 mm), and Grade 3 lesions.
atients with T3–T4 lesions, very small or very large breasts, a
ery eccentric tumor bed localization, or a history of breast recon-
truction were excluded. Patients either not able to have a com-
uted tomographic (CT) or magnetic resonance imaging (MRI)
can (due to, for example, claustrophobia) or those who refused to
ave such a scan, as well as those who were not capable of
nderstanding basic radioprotection rules, or who were involved in
he daily care of young children, were not entered. We treated
atients with or without the presence of surgical clips placed
uring initial surgery to help identify the target volume. No che-
otherapy was ongoing during the external beam radiotherapy or
lanned for afterwards. Patients were offered this permanent im-
lant boost method, which is now well established in numerous
natomic regions of the body, as an alternative to the classical
ridium boost. The differences explained included the greater do-
imetric selectivity and the radioprotection rules. Patients were
learly informed about the technique and agreed to the treatment.
xternal beam radiotherapy
Patients underwent classical external beam adjuvant whole-
reast radiotherapy to a dose of 46–50 Gy in 23–25 fractions using
ig. 1. Breast immobilization with a thermoplastic sheet. The
atient is placed on a base plate and arms are positioned on a blue
rmrest (1). The yellow thermoplastic sheet is fixed to the base
late with green table inserts (2). The needle-guiding template has
een removed to show the blue marking points on the thermoplas-
ic sheet, such as nipple, scar, and tattoo points (3).wo opposed tangential, wedged, nonisocentric beams with a t-megavolt linear accelerator or a cobalt60 machine. Treatments
ere given over a 5–6-week period. The dose was reported ac-
ording to International Commission on Radiation Units and Mea-
urements guidelines (8).
rachytherapy simulation
Simulation was performed using the “all in 1” (AIO) immobi-
ization system (Orfit Industries, Wommelgem, Belgium), which
onsisted of an indexed base plate on the table; head-and-neck
upports; and arm, knee, back, and ankle cushions. The patient was
laced in a supine position, with both arms behind the head
Fig. 1). Under fluoroscopic control, the isocenter was placed in
he middle of the tumor bed, as indicated by radiopaque surgical
lips. In the absence of these markers, the tumor bed was identified
ased on clinical examination, ultrasound and mammography data.
ithout changing the isocenter, the gantry was turned to check at
hich angle the tumor bed did not project onto the lungs or the
horacic wall. This gantry angle defined the directional axis for
he later needle implant. A heated, thick, perforated thermo-
lastic sheet of 35 cm  45 cm (Orfit Industries, Wommelgem,
elgium) was placed on the thorax, molded around both
reasts, and fixed to the immobilization plate using small inserts
xed to the sheet (Fig. 1).
We developed a new “template bridge” consisting of a parallel
edial and a lateral perforated template, each with a thickness of
.7 cm and linked by a slidable arm (Fig. 2). This was applied on
he thermoplastic sheet at the level of the breast, slightly com-
ressing it during the cooling phase. The templates were placed so
hat, as far as possible, they were perpendicular to the directional
xis. The isocenter was once more checked, and a set of orthogonal
eference radiographs were obtained. Six tattoo points were avail-
ble from previous external beam radiotherapy (3 medial and 3
ig. 2. Needle-guiding template bridge. A clear, yellow thermo-
lastic sheet is molded around the breast. A slidable, white tem-
late bridge mildly compresses the breast. Black lines indicate the
xes and the isocenter. The red line and dots mark, respectively, a
car and tattoo points. Markers that are compatible with magnetic






















































1054 I. J. Radiation Oncology ● Biology ● Physics Volume 67, Number 4, 2007ateral, at the base of the breast, equally spread in the cranio-caudal
irection). These tattoo points were the main reference points that
ere marked on the thermoplastic sheet. Other points included
ipple position and scars. These references enabled the thermo-
lastic sheet to be replaced, during subsequent stages, in exactly
he same position on the breast and on the base plate, thus offering
reproducible immobilization. The fixed head support and arm
ushion also forced the patient to remain in the same position.
uring simulation, the breast was photographed to document the
rocedure. The cosmetic state of the breast was evaluated by both
atient and physician, using the categories “excellent”, “good”,
reasonable”, and “bad”.
maging
Magnetic resonance imaging/CT-compatible markers were
laced on the corners of the external surface of the medial and
ateral templates and on the nipple. The sheet was repositioned
xactly using the reference and tattoo points for guidance. A set of
1 and T2 images (MRI) or CT images were obtained, scanning
he whole ipsilateral thoracic area, the heart, and the whole tem-
late bridge. Slices were 3 mm thick and were obtained every 3
m. The images were then sent to the treatment planning system
orkstation.
arget volume definition and preplanning
The image set was first imported into a custom-made application
nown as Slicer (Socobel, Waterloo, Belgium), which recon-
tructed planes perpendicular to the directional axis, thus parallel
o the templates. These reconstructed images were then sent to the
Fig. 3. (a) Preplan dosimetry. The skin is indicated in l
opaque marker that is placed on the nipple is visible in w
placed white dots: the columns are marked 1 to 10 and t
this plane. Open yellow dots indicate the presence of see
yellow line indicates the prescription isodose of 50 Gy.
orange line indicates the 20 Gy isodose line. (b) Postplan
and the heart in dark green. The large red dots indicate
prescription isodose of 50 Gy. The soft pink line indica
20 Gy isodose line. The good protection of skin, heart,rowess brachytherapy treatment planning system (v4.2; Prowessnc., Chico, CA). A virtual template was applied, with a distance
etween the needle rows and columns of 10 mm, which corre-
ponded to the holes that were drilled in the templates. For this
eries of patients, the implant direction selected was from lateral to
edial. The CTV was defined as the tumor bed, as indicated by
lips, seroma, and scar tissue plus a margin of 20 mm, without
oing into skin or thoracic cage, but extending to the retro-areolar
rea—this amounted, in practice, to a breast quadrant. Additional
nformation used for setting the CTV location, certainly in the
bsence of markers in some patients, was the preoperative set of
ammographies, a postoperative breast ultrasound performed for
his purpose, clinical data from the patient file, and the pathologic
eport. Skin was defined as a 4–5-mm-wide structure, taking into
ccount that skin toxicity can depend on doses to skin vasculature
hat can be found in this range (9). Organs at risk (skin, lung, and
eart) and CTV were delineated on the reconstructed slices. Vir-
ual iodine-125 sources, at a minimum distance of 10 mm from
ach other, were then applied in a staggered manner. They were
laced in and around the CTV, avoiding sources close to the skin
r the thoracic wall (Fig. 3a). Only strands were allowed.
rescription dose
The time–dose factor (TDF) of a “classical” external beam
oost of 16 Gy in 8 fractions of 2 Gy at 5 fractions per week is 26
10). For a permanent seed implant, the total dose D in cGy and
DF are related by Eq. 1, where  is the decay constant of the
sotope (10, 11).
TDF 0.7407
een, the lung in pink, and the heart in dark green. An
he template positions are shown by the small, regularly
s A to E. The large red dots indicate source positions in
ther planes. The target volume is indicated in blue. The
oft pink line indicates the 30 Gy isodose line; the light
try. The skin is indicated in light green, the lung in pink,
e positions in this plane. The yellow line indicates the
30 Gy isodose line; the light orange line indicates the





























































































1055Breast adjuvant permanent seed implant ● N. JANSEN et al.n this case, the decay constant  for iodine-125 is defined by Eq.
, with the t1/2 (half-life) of iodine-125 being 1,425.6 h.
  ln(2)t1⁄2 h1 4.8621 104 (2)
rom Eqs. 1 and 2, the calculated theoretical dose is 52.9 Gy.
aking into account the given dose by external radiotherapy, and
ased on our prostate experience, we selected 50 Gy given at a
ery low dose rate as the prescription dose (PD) for this boost
reatment. In previously published work on permanent breast seed
mplants, a similar approach was used (12). The 50 Gy isodose line
hould cover the CTV on the preplan with, for as far as possible,
margin of 5 mm to compensate for the possible seed shift during
he implantation procedure. D90 was the dose delivered to 90% of
he CTV. CTV V50 Gy (volume receiving 50 Gy) and CTV V100
y were the CTV volumes receiving 100% or 200% of the
rescribed dose. For skin, heart, and lung, the V5 Gy, V15 Gy, and
30 Gy were the organ volumes receiving doses of 5 Gy, 15 Gy,
nd 30 Gy. We tried to avoid giving more than 30 Gy to the skin,
ccepting however local hotspots. This skin dose level corresponds
o two-thirds of the prescribed dose, which is similar to our
xperience in high-dose-rate breast boosting. Finally, the total
olume of breast receiving 100% and 200% of the PD was defined
s Total Breast V50 Gy and V100 Gy. Volumes irradiated were
eported in milliliter. All these preplan dose–volume histogram
ata were noted, and an implant report was printed for use in the
perating theater.
atient preparation
The whole procedure was carried out at the one-day clinic.
he patients were placed on the standardized “all in 1” system
n the simulated position and brought under general anesthesia.
he thermoplastic sheet was disinfected by spraying it with an
odine solution (Isobetadine) and then placed onto the patient.
he breast itself was repositioned inside the sheet using previously
arked reference points (tattoos, scars, and the nipple position).
oles cut out in the thermoplastic sheet permitted final adjust-
ents to be made to the breast position by the insertion of fingers.
hese holes also allowed needles to pass through the thermoplastic
heet. The gas-sterilized slidable bridge was then applied on the
utside of the thermoplastic sheet in the imprint that was made
uring initial simulation. The distance between the templates was
arefully checked. A single dose of corticosteroids (methylpred-
isolone 125 mg) was given to prevent excessive breast swelling.
eedle implantation procedure
First, one or more stabilization needles were placed in the upper
lane(s) to avoid displacement of the breast. Following the implant
cheme, needles were inserted, such as is done during prostate
rachytherapy. They traveled through the breast and came out on
he other side, guided by the templates. If the rigid needle easily
ppeared on the other side of the breast at the corresponding
emplate hole, it was concluded that the trajectory was satisfactory.
o avoid damaging the tips of the implant needles by breast tissue,
kin, or templates, we first inserted a rigid needle with a trocar that
ad a pyramidal tip. The trocar was then retracted, leaving behind
he needle cannula that linked both templates. A fine, long guid-
nce trocar, without any extremity button, was then inserted into
he cannula. The initial cannula was retracted and the definitive
mplant needle was carefully pushed over the long, fine guidance brocar, which was then retracted and replaced by the implant
eedle’s own trocar. Source insertion was only started after all
eedles had been inserted.
ource insertion
Iodine-125 strands consisting of 10  0.300 milliCurie seeds
IBt, Seneffe, Belgium) were cut to the correct length and seeds
ere calibrated just before the implant procedure. Needle by
eedle, the trocar was removed, and a source transfer container
as attached. The strand was inserted and pushed by a thick trocar
hat was adapted to the transfer container. The needle was retracted
o the correct insertion depth from the external surface of the
ateral template, as calculated during preplanning, and the seeds
ere inserted as is done for prostate implants. Before and after
ach strand insertion, a rapidly obtained fluoroscopic image was
nspected on the screen to confirm correct placement. At the end of
he procedure, the template bridge was removed and seed place-
ent was again checked under fluoroscopy. This was repeated
fter removal of the thermoplastic sheet, with the breast in a
elaxed position (Fig. 4). The breast was gently cleaned, and
eneral anesthesia was ended. The patient was then asked to wear,
s often as possible, a solid sports bra to reduce breast movements.
adioprotection
The same precautions were taken and the same material used as
or prostate implants. The patient was instructed to avoid close and
rolonged personal contact with others for the next 3 months.
ostimplant plan
On Day 14, a postplan CT of the breast with a sports bra was
ade. The patient was placed in a supine position. The same CT
arameters were used as for the preplan CT. The same structures
ere delineated except for CTV (Fig. 3b). Total Breast V50 Gy
ig. 4. Postimplant fluoroscopic image obtained after removal of
he thermoplastic sheet showing the implanted strands. The two
ateral opaque lines indicate the limits of the breast. The central
paque marker tip indicates the nipple location. The tumor was








































































1056 I. J. Radiation Oncology ● Biology ● Physics Volume 67, Number 4, 2007nd V100 Gy were calculated, as well as the different doses for
kin, lung, and heart. The statistical comparisons between preplan
nd postplan data were performed using a paired bilateral Student
test.
ollow-up
Each patient was seen 2–3 weeks and 3 months after the implant
rocedure, and their progress was followed according to existing
ocal guidelines. Cosmetic evaluation was planned from a 1-year
ollow-up onwards.
RESULTS
atient, tumor, and breast characteristics
One of 3 patients to whom the technique was proposed
efused this treatment modality, mainly due to concerns
egarding their ability to respect radioprotection guidelines.
rom March to December 2005, 15 female patients were
reated. The median age was 55 years (range, 41–74 years).
ive patients had a left-sided and 10 patients had a right-
ided breast tumor. Three patients were premenopausal at
he time of implant.
Most tumors were early: 13 T1 and 2 T2 lesions (TNM
lassification, International Union Against Cancer [UICC],
th edition, 2002). The median maximal diameter was 13
m (range, 6–37 mm). Ten patients were node-negative
nd 5 had axillary N1 involvement. Three patients had an
nvasive lobular carcinoma, the others had an invasive duc-
al carcinoma. No patient had distal metastases. Evaluation
y both patient and physician showed that all breasts were
n an “excellent” or “good” cosmetic state before the im-
lant.
replanning data
The median number of needles used was 14 (range,
–20); the median number of seeds per patient was 52
range, 29–80). The mean preplan CTV volume was 58 
3.2 mL. For a PD of 50 Gy, we observed a mean CTV D90
f 66  14.9 Gy, a mean CTV V50 Gy of 97  3.9%, and
mean skin V30 Gy of 6  3.9 mL. Heart data were based
n the 5 patients with a left-sided tumor. For every patient, the
eart V30 Gy was zero mL. The mean lung V30 Gy was 1.4
2.5 mL. The mean total breast V50 Gy and V100 Gy were
05  41.4 mL and 37  20 mL, respectively (Table 1).
mplant procedure
The median time between external radiotherapy and
reast implant was 13 days (range, 3–19 days). The median
uration of general anesthesia was 150 min. The fluoro-
copic images that were obtained at the end of the implant
rocedure with and without the thermoplastic sheet were
ompared (Fig. 4). Seeds remained in place, notably within
he planned breast quadrant, except for three strands that
ere not optimally placed owing to technical difficultiesuch as bleeding inside the implant needle. iostimplant plan
Mean skin V30 Gy was 2  2.2 mL. Mean skin V50 Gy
as below 0.1 mL. We observed hotspots, the mean max-
mal skin dose in 1 point being 65 35 Gy. Mean heart V30
y was 0.24  0.34 mL, and mean lung V30 Gy was 3.5 
mL. Mean total breast V50 Gy decreased from 105  41
L in preplans to 96  37 mL in postplans (p  0.007).
ean total breast V100 Gy did not change significantly
Table 1).
hort-term follow-up data
At the time of the postimplant CT scan, little toxicity was
oted that could not be attributed to the previous external
eam radiotherapy or the brachytherapy procedure. It con-
isted of Grade 1 skin toxicity, mild breast edema, and
enderness. The small scars from the individual needles
ere still visible at that time. One patient had a hematoma,
nd 1 patient complained of persisting fatigue. One patient
eveloped a transient, totally reversible Grade 3 bilateral
pper-limb neuropathy. At a mean follow-up of 10  2.5
onths, no other apparent treatment-related toxicity or local
elapses were noted.
DISCUSSION
We have described a new technique for the permanent
Table 1. Dose–volume histogram data for a prescribed dose of
50 Gy (VLDR) (n  15)
Preplan Postplan
mean  SD mean  SD p*
TV
Volume 58 mL 23.2
D90 66 Gy 14.9
V50 Gy 97% 3.9
V75 Gy 78% 11.4
V100 Gy 50% 19.3
kin
V5 Gy 50 mL 11.6 53 mL 10.1 0.102
V30 Gy 6 mL 3.9 2 mL 2.2 0.003
V50 Gy 0.43 mL 1.4 0.09 mL 0.12 0.375
eart†
V15 Gy 0.06 mL 0.13 4.7 mL 5.6 0.133
V30 Gy 0.0 mL 0 0.24 mL 0.34 0.186
ung
V15 Gy 15 mL 13.6 22 mL 19.9 0.145
V30 Gy 1.4 mL 2.5 3.5 mL 5.0 0.104
otal breast
volume
V50 Gy 105 mL 41.4 96 mL 37.1 0.007
V100 Gy 37 mL 20 34 mL 16.4 0.458
Abbreviations: CTV  clinical target volume; Gy  Gray;
LDR  very low dose rate; V  volume; V50 Gy  volume in
L receiving a dose of 50 Gy; D90  dose in Gray received by
0% of a volume; SD  standard deviation.
* Paired bilateral Student t test.










































































































1057Breast adjuvant permanent seed implant ● N. JANSEN et al.nserting seeds in a soft organ such as the breast does require
ew tools. We developed an adapted breast immobilization
ystem, a slidable needle-guiding template bridge, a specific
imulation procedure, a new image rotating application, and a
replan-based implant technique for the breast.
In our experience, it can be difficult to appreciate the
elationship between needles and CTV using a reference
eedle under ultrasound control (12). Therefore, we devised
stereotactic system, based on immobilizing the breast with
thermoplastic sheet that can be precisely repositioned
sing a set of reference points on the sheet and on the
atient’s skin. Compared with other partial breast irradia-
ion techniques using iridium-192, the whole brachytherapy
rocedure can be carried out in a 1-day clinic after simula-
ion and scanning on an outpatient basis.
In general, seed deposits looked correct as indicated by
ostoperative fluoroscopic checks, except for three strands that
ad not been optimally placed because of technical difficulties
uch as bleeding inside the implant needle. Should the fluoro-
copic evaluation after each strand insertion show a suboptimal
lacement, the problem can still be corrected intraoperatively,
y adding extra seeds to the areas missed.
In this analysis, which aimed to cover a whole quadrant
hile sparing critical organs, no clinically relevant shift of
eeds toward the skin or thoracic wall was observed as skin,
eart, and lung volume histogram data did not change signif-
cantly from pre- to postplan; the only exception was for skin
30 Gy (Table 1). Total breast V50 Gy decreased slightly on
ostplans (p 0.007), with a mean difference between the pre-
nd postimplant of 9.21  11.2 mL (confidence interval,
.55–14.9). Meanwhile the total breast V100 Gy did not
hange significantly. We thus assume that the mild seed shift
as a limited dosimetric impact on the periphery of the implant,
ather then in the center of the implant where the hyperdosage
reas are to be found. Should we want to account for this
henomenon, the security margin taken around the CTV on the
replan can be enlarged. As the initial tissue repair occurs
ormally within 2 weeks, we do not expect strands to move
fter the postplan evaluation. We conclude that, as with per-
anent prostate implants, postplan analysis shows a slight but
cceptable degradation of the ideal plans that were designed
reoperatively.
The apparently high mean preplan Total Breast V50 Gy
105 mL), in comparison with the mean CTV volume (58
L), can be explained by our loading method, which aims
o surround the whole CTV to compensate for possible seed
hifts as discussed above. Taking a 5-mm margin in all
irections around a spherical volume of 58 mL leads more
r less to a 105-mL volume. However, the mean postplan
50 Gy value remains largely below 150 mL, which is the
utoff value for the appearance of late side effects in a
revious breast brachytherapy series (13).
We observed no adverse reactions or other important side
ffects except for a transient bilateral Grade 3 neurologic
oxicity in 1 patient. We have, at present, no clear explana-
ion for this temporary problem, but we suggest that it might
ave been related to the extension of both arms or to neck 1anipulation during the implant procedure. The short fol-
ow-up does not permit us to come to any conclusions about
umor control or cosmetic outcome.
The prescription dose of 50 Gy (very low dose rate) was
alculated on the basis of previously published data using
he TDF approach (10–12). We also recalculated the bio-
ogically equivalent dose (BED) of this treatment, taking
nto account repair and repopulation of breast tissues
14, 15), and obtained with an alpha/beta ratio of 10 Gy for
arly and tumor effects a BED in Gy10 that is similar to the
lassical 16 Gy boost in eight fractions. The BED in Gy3 for
ate effects in healthy tissues seems, on the other hand, to be
igher than for the classical external approach. This is
ainly the case for the high dose areas inside the CTV; the
rgans at risk around the CTV (skin and subcutaneous
issue, heart, and lung) receive a much lower dose because
f the rapid dose fall-off and the dosimetric selectivity of
his treatment, translating into a low BED. The mean post-
lan skin V30 Gy ( 60% of the prescription dose) is, for
nstance, only 2 mL, corresponding to a BED of 26 Gy3 at
his point, which is equivalent to the classical treatment. It
emains to be seen if these differences will lead to a differ-
nt local late toxicity profile.
Target definition remains a challenging point in breast
rachytherapy. In the present series, we wanted to treat a
arge boost volume (a breast quadrant) to a relatively low
oost dose (16). This explains why, contrary to what is
roposed in the Groupe Européen de Curiethérapie—Euro-
ean Society for Therapeutic Radiology and Oncology
GEC-ESTRO) randomized partial breast irradiation proto-
ol, the margin is not adapted in function of the surgical
argins that have already been taken, and “high-risk” pa-
ients were included. The absence of markers in some pa-
ients or the difficulty to distinguish seeds from markers of
he tumor bed did contribute to the complexity of postplan
nalysis. Moreover, the breast position on postplans was
lightly different because there was no compression by the
hermoplastic sheet. Furthermore, the scan orientation is dif-
erent as axial slides are obtained for the postplan, in contrast
o the preplan reconstructed slides that are perpendicular to the
irectional axis. It is, of course, possible to obtain a postplan
mage series with the thermoplastic sheet in place, but this does
ot constitute a real treatment situation, even with patients
ontinuously wearing a sports bra to reduce breast movements.
inally, most of the previously described breast brachyther-
py treatments using plastic tubes, from which good results
ere reported, were also done on organs that do not remain
mmobile for the duration of the whole treatment (2). For all
hese reasons, we decided not to indicate CTV structures on
ostplans. We realize that, in future, we should be able to
ore precisely identify the postplan CTV and we are cur-
ently working on new ways to define, even before surgery,
ts future borders.
Because the breast is more exposed than the prostate area,
here is a higher dose rate at 1 m from the patient. For the
oost technique described with a low PD and using iodine-














































1058 I. J. Radiation Oncology ● Biology ● Physics Volume 67, Number 4, 2007ot show a dose rate beyond safe or legal limits (17). A
igher PD for exclusive breast treatments might require a
arger number of seeds or a higher seed activity, or both.
his could increase the dose rate at 1 m in air beyond
cceptable limits, unless palladium-103 seeds rather than
odine-125 seeds are used (18).
Dose inhomogeneity is inherent to all brachytherapy
reatments, and particularly in the center of larger implants
ontinuous high dose areas tend to be present. Should we
ant to avoid this, it is possible to use a different loading
attern or two or more different seed activities, placing the
ower activity strands in the center of the implant.
This analysis was considered to be a necessary prelimi-
ary step before starting with partial breast irradiation with
ermanent implants in a prospective trial. We think, how-
ver, that the present method could also be proposed as a
oost in cases in which a high dosimetric selectivity might
e required, such as when young patients with left-sided
reast cancer have previously been treated with cardiotoxic
hemotherapy. Reducing heart doses can be expected to
ecrease long-term cardiac toxicity (19). Preimplant and
ostimplant dose–volume histogram data do, indeed, show
ow heart, lung, and skin doses. Moreover, all these doses
re given at a very low dose rate that protects critical organs. p
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ds are presently being developed for precise external
eam treatment, but in an organ such as the breast, close
o the heart and continuously moving with respiration,
rachytherapy remains an interesting technique for im-
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